Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine

Interventional, Open-label, Two Single Dose, Fixed-sequence Study Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine Following a Single Oral Dose of Lu AF67708 ([Ethyl-1-14C]-Idalopirdine) and Lu AF67709 ([Benzyl-7-14C]-Idalopirdine) in Healthy Men

The purpose of this study is to investigating the absorption, metabolism and excretion of radio labelled single doses of idalopirdine in healthy men.

Inclusion Criteria:

• Healthy men
• aged between 40-60 years (inclusive)
• BMI in the range 19 and 30 kg/m2 (minimum weight 60 kg)

Exclusion Criteria:

• The subject has previously been dosed with idalopirdine.

Other protocol defined inclusion and exclusion criteria do apply